Comprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com

The “Global Covid-19 Diagnostic Market Forecast by Technology, Product, Channel and Country with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Amidst signs of the pandemic easing, Covid-19 continues to reshape markets, especially in the realm of respiratory diagnostics, where a…

Read MoreComprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com

2024 Biopharma-Site Network Pulse Report: Insights from IQVIA, ICON, Parexel, Fortrea, PPD/Thermo Fisher, and Syneos Health – Research And Markets.com

The “2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report” has been added to ResearchAndMarkets.com’s offering. The landscape of biopharmaceutical clinical development is in a constant state of flux and progression. While major global Contract Research Organizations (CROs) cater to a significant portion…

Read More2024 Biopharma-Site Network Pulse Report: Insights from IQVIA, ICON, Parexel, Fortrea, PPD/Thermo Fisher, and Syneos Health – Research And Markets.com

Otsuka Pharma’s Indonesian Subsidiaries Earn Exemplar Award from EWTB for Tuberculosis Eradication Efforts

Otsuka Pharmaceutical proudly announces that its subsidiaries in Indonesia, PT Otsuka Indonesia (PTOI) and PT Amerta Indah Otsuka (PTAIO), have been honored with the prestigious 2024 Ending Workplace Tuberculosis (EWTB) Exemplar Award. This esteemed recognition, coinciding with World TB Day…

Read MoreOtsuka Pharma’s Indonesian Subsidiaries Earn Exemplar Award from EWTB for Tuberculosis Eradication Efforts

CHMP Recommends Novartis Fabhalta® for Adult Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis Unveils Positive CHMP Endorsement for Fabhalta® in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion, recommending the authorization…

Read MoreCHMP Recommends Novartis Fabhalta® for Adult Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bio-Techne Attains European IVDR Certification for Diagnostic Test Monitoring Chronic Myeloid Leukemia

Bio-Techne Corporation (NASDAQ: TECH) has announced today that its Molecular Diagnostics Division, Asuragen, has successfully obtained Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. This certification marks a…

Read MoreBio-Techne Attains European IVDR Certification for Diagnostic Test Monitoring Chronic Myeloid Leukemia

UCB’s BIMZELX[®]▼ (bimekizumab) Gains Favorable CHMP Opinion for treatment Moderate to Severe Hidradenitis Suppurativa in Adults

UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion, recommending the granting of marketing authorization for BIMZELX® (bimekizumab) within…

Read MoreUCB’s BIMZELX[®]▼ (bimekizumab) Gains Favorable CHMP Opinion for treatment Moderate to Severe Hidradenitis Suppurativa in Adults

Bayer and Trinity Agtech Collaborate to Advance Regenerative Agriculture Practices

In a strategic move towards advancing regenerative agriculture, Bayer has announced a partnership with Trinity Agtech, a UK-based company. This collaboration aims to leverage Trinity Agtech’s platform, Sandy, as a cornerstone in Bayer’s Carbon Initiative across the EMEA region, facilitating…

Read MoreBayer and Trinity Agtech Collaborate to Advance Regenerative Agriculture Practices